NEU · ASX

Neuren Pharmaceuticals Limited (ASX:NEU)

AU$13.27

 0.23 (1.764%)
ASX:Live
21/02/2025 04:10:56 PM
Recent Price downgrade Recent Earnings upgrade HALO Value HALO Small HALO Ords +10
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NEU Overview

NEU Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Very Weak

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Weak

Balance Sheet

Very Weak

About NEU

Website

Neuren Pharmaceuticals Limited

Telephone

61.3.9092.0480

Address

Suite 201 697 Burke Road Camberwell, Victoria (VIC) 3124

Description

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.

NEU Price Chart

Key Stats

Market Cap

AU$1.74B

PE

14.30

EV/EBITDA

11.3

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 10.9 - 24.0

Trade Value (12mth)

AU$2,076,430.00

1 week

-0.53%

1 month

-4.12%

YTD

6.45%

1 year

-35.22%

All time high

25.95

Key Fundamentals

EPS 3 yr Growth

-1539.10%

EBITDA Margin

85.90%

Operating Cashflow

$185m

Free Cash Flow Return

149.90%

ROIC

127.30%

Interest Coverage

N/A

Quick Ratio

5.80

Other Data

Shares on Issue (Fully Dilluted)

131m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

4.21

NEU Announcements

Latest Announcements

Date Announcements

19 February 25

Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins

×

Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins

07 February 25

Type C Meeting granted by FDA for Phelan-McDermid syndrome

×

Type C Meeting granted by FDA for Phelan-McDermid syndrome

07 February 25

Priority Review Voucher sale proceeds received

×

Priority Review Voucher sale proceeds received

06 February 25

Neuren to present at autism research meeting

×

Neuren to present at autism research meeting

22 January 25

NEU Presentations at ACMG Annual Clinical Genetics Meeting

×

NEU Presentations at ACMG Annual Clinical Genetics Meeting

20 January 25

J.P. Morgan Healthcare Conference recap

×

J.P. Morgan Healthcare Conference recap

16 January 25

Neuren JP Morgan Healthcare Conference 2025 presentation

×

Neuren JP Morgan Healthcare Conference 2025 presentation

15 January 25

Trofinetide marketing application submitted in Europe

×

Trofinetide marketing application submitted in Europe

18 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

17 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

16 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

13 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

12 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

12 December 24

Priority Review Voucher sale complete

×

Priority Review Voucher sale complete

11 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

10 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

09 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

06 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

05 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

04 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

03 December 24

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

15 November 24

Investor presentation, 15 November 2024

×

Investor presentation, 15 November 2024

14 November 24

Neuren announces A$50m on-market share buy-back program

×

Neuren announces A$50m on-market share buy-back program

14 November 24

Notification of buy-back - NEU

×

Notification of buy-back - NEU

07 November 24

Pause in Trading

×

Pause in Trading

NEU Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 0.00 1.24 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 0.00 1.20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.9 102.3 82,313.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 1,826.7 14.3 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 334.9 11.3 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 0.02 1.27 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.08 0.03 1.41 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.9 142.7 5,119.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.2 0.3 5.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.30 0.33 1.61 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.30 0.33 1.61 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.9 8.5 388.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 118 129 131 Lock Lock Lock
Basic m Lock Lock Lock Lock 118 126 127 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 15 232 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A 1,493.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 16 33 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 15 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.3 181,887.5 -100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 99.9 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -2 199 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.0 86.1 12,662.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -10.9 85.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -2 199 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.0 86.0 12,583.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -11.0 85.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -1 205 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -1 48 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 0 157 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.2 102.4 85,270.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 1.3 67.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 4 185 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -211 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 22 0 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -10 4 185 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.5 135.9 5,064.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 0.2 0.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 37 40 229 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 40 43 248 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -37 -40 -229 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 43 Lock Lock Lock
Equity $m Lock Lock Lock Lock 39 42 205 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 39 42 205 Lock Lock Lock
     Growth % Lock Lock Lock Lock 62.2 6.0 393.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -19.5 0.4 63.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -19.9 0.4 76.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -36.0 -3.9 161.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -24.6 0.5 127.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -31.4 8.9 149.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.2 25.3 -1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.7 -96.6 -111.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 49.9 25.8 5.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 49.9 25.8 5.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 91.9 92.9 92.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,241.6 214.5 432.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 11.6 29.9 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.4 1.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 1.8 0.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.9 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.9 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 -4.7 88.4 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 -1.6 82.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 23.4 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -19.5 0.4 63.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -19.9 0.4 76.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -19.9 0.4 76.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 31.5 12.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 31.5 12.2 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 9,407.2 9,170.9 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -9,407.2 -9,139.3 12.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

4.21%

Value ($M)

71

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.30%

3 Month Change

1.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NEU Shortsell

Frequently Asked Questions

The current share price of Neuren Pharmaceuticals Limited (NEU:ASX) is AU$13.27.
The 52-week high share price for Neuren Pharmaceuticals Limited (NEU:ASX) is AU$24.00.
The 52-week low share price for Neuren Pharmaceuticals Limited (NEU:ASX)? is AU$10.90.
The current TTM dividend payout for Neuren Pharmaceuticals Limited (NEU:ASX) is 0.00.
Neuren Pharmaceuticals Limited (NEU:ASX) does not pay a dividend.
Neuren Pharmaceuticals Limited (NEU:ASX) has a franking level of 0.0%.
Neuren Pharmaceuticals Limited (NEU:ASX) is classified in the Healthcare.
The current P/E ratio for Neuren Pharmaceuticals Limited (NEU:ASX) is 14.30.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.